"atacicept" meaning in English

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "atacicept (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        }
      ],
      "examples": [
        {
          "bold_text_offsets": [
            [
              242,
              251
            ]
          ],
          "ref": "2009 July 20, Andrew Pollack, “Trial for New Lupus Treatment Is Called Promising”, in New York Times:",
          "text": "Among the companies that have had setbacks or outright failures in clinical trials are Roche and Biogen Idec with their drug Rituxan; La Jolla Pharmaceutical with Riquent; Bristol-Myers Squibb with Orencia; ZymoGenetics and Merck Serono with atacicept; Genelabs Technologies with Prestara; Teva Pharmaceutical Industries with edratide; and Aspreva Pharmaceuticals and Roche with CellCept.",
          "type": "quote"
        }
      ],
      "glosses": [
        "A recombinant fusion protein designed to inhibit B cells, thereby suppressing autoimmune disease."
      ],
      "id": "en-atacicept-en-noun-3i1zwPEv",
      "links": [
        [
          "recombinant",
          "recombinant"
        ],
        [
          "fusion protein",
          "fusion protein"
        ],
        [
          "B cell",
          "B cell"
        ],
        [
          "autoimmune",
          "autoimmune"
        ]
      ],
      "tags": [
        "uncountable"
      ],
      "wikipedia": [
        "atacicept"
      ]
    }
  ],
  "word": "atacicept"
}

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "atacicept (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms with quotations",
        "English uncountable nouns",
        "Pages with 1 entry",
        "Pages with entries"
      ],
      "examples": [
        {
          "bold_text_offsets": [
            [
              242,
              251
            ]
          ],
          "ref": "2009 July 20, Andrew Pollack, “Trial for New Lupus Treatment Is Called Promising”, in New York Times:",
          "text": "Among the companies that have had setbacks or outright failures in clinical trials are Roche and Biogen Idec with their drug Rituxan; La Jolla Pharmaceutical with Riquent; Bristol-Myers Squibb with Orencia; ZymoGenetics and Merck Serono with atacicept; Genelabs Technologies with Prestara; Teva Pharmaceutical Industries with edratide; and Aspreva Pharmaceuticals and Roche with CellCept.",
          "type": "quote"
        }
      ],
      "glosses": [
        "A recombinant fusion protein designed to inhibit B cells, thereby suppressing autoimmune disease."
      ],
      "links": [
        [
          "recombinant",
          "recombinant"
        ],
        [
          "fusion protein",
          "fusion protein"
        ],
        [
          "B cell",
          "B cell"
        ],
        [
          "autoimmune",
          "autoimmune"
        ]
      ],
      "tags": [
        "uncountable"
      ],
      "wikipedia": [
        "atacicept"
      ]
    }
  ],
  "word": "atacicept"
}